Telehealth Weight Loss/GLP-1 Prescribing: What Psychiatrists Can Do in Pennsylvania

Last updated: July 8, 2026

If you’re a psychiatrist or psychiatric nurse practitioner watching the GLP-1 boom and wondering whether you can (or should) prescribe weight-loss medications, you’re not alone. The answer isn’t as simple as ‘yes’ or ‘no’ — it depends on your state, your credentials, and how you approach scope of practice. But here’s the bottom line: many psychiatric providers are already doing this, and with the right framework, you can too.

This guide breaks down the legal, clinical, and business realities of prescribing weight-loss medications as a mental health provider — from understanding state-by-state regulations to navigating insurance coverage and telehealth rules.

Why Psychiatrists Are Entering the Weight-Loss Space

Let’s start with the obvious question: Why would a psychiatrist prescribe Wegovy or phentermine?

Because metabolic health and mental health are inseparable. Many of your patients struggle with obesity — often as a direct consequence of psychiatric medications. Antipsychotics, mood stabilizers, and even some antidepressants cause significant weight gain. For years, we’ve treated the mental health condition while watching patients develop diabetes, hypertension, and deteriorating self-esteem from medication-induced obesity.

GLP-1 receptor agonists (semaglutide/Wegovy, tirzepatide, liraglutide/Saxenda) have changed the game. These aren’t just diet pills — they’re medications that address the biological drivers of obesity, reduce cravings, and in many cases, improve mental health outcomes independently of weight loss. Studies show reduced depression scores, improved quality of life, and potential benefits for substance use disorders.

Dr. Elliott Lewis, a board-certified psychiatrist and obesity medicine specialist, argues that managing obesity falls squarely within psychiatric scope when done competently: ‘If we truly understand that these systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ He notes that psychiatrists already monitor metabolic parameters (glucose, lipids) for patients on psychiatric drugs — prescribing a GLP-1 to address those issues is a logical extension of integrated care.

The key word is ‘competency.’ You don’t need to become an endocrinologist, but you do need to understand obesity pharmacotherapy, contraindications, side effects, and monitoring protocols. Many psychiatrists pursue additional training — some even obtain board certification in obesity medicine (yes, psychiatrists are eligible for the American Board of Obesity Medicine credential).

Scope of Practice: Can You Legally Prescribe?

Psychiatrists (MD/DO)

Short answer: Yes, in all 50 states. As a fully licensed physician, you have broad prescriptive authority. There’s no legal prohibition on psychiatrists prescribing FDA-approved weight-loss medications or using drugs like metformin off-label for metabolic issues.

However, state medical boards may have specific rules about how you prescribe obesity medications:

• Florida requires documented BMI ≥30 (or ≥27 with comorbidities), comprehensive physical exam, written informed consent, and follow-up visits at least every 3 months for anyone on weight-loss drugs. You must also provide patients with Florida’s ‘Weight-Loss Consumer Bill of Rights.’
• New Jersey mandates a complete workup (history, physical, labs, psychiatric assessment) before prescribing, plus documented nutritional counseling and exercise recommendations — not just pills.
• Virginia requires an initial exam and follow-up within 30 days of starting therapy, then regular monitoring.

The clinical standard across states generally aligns with FDA labeling: prescribe anti-obesity medications to patients with BMI ≥30 or ≥27 with obesity-related comorbidities (diabetes, hypertension, etc.), obtain informed consent, and monitor regularly.

Bottom line for MDs: You can prescribe these medications, but you must follow state-specific clinical protocols and document appropriately. Treating obesity isn’t ‘outside your scope’ if you’re competent and practicing standard care.

Psychiatric Nurse Practitioners (PMHNPs)

It’s more complicated. Your ability to prescribe weight-loss medications depends entirely on your state’s nurse practice act and whether you have full practice authority (FPA).

In ~24 states with Full Practice Authority, experienced PMHNPs can prescribe independently after meeting requirements (typically 2,000–4,600 hours of supervised practice). States like New York (after 3,600 hours), Illinois (after 4,000 hours + 250 CE hours), and eventually California (under AB 890, effective 2026 for ‘104’ NPs) allow NPs to practice and prescribe without physician oversight.

In the other ~26 states, you’ll need a collaborative agreement with a physician to prescribe anything, including weight-loss medications. States like Texas and Florida require formal Prescriptive Authority Agreements that explicitly authorize what you can prescribe. In Texas, your collaborating physician must conduct monthly chart reviews and meet with you regularly. In Florida, even ‘autonomous’ NPs (a limited designation for primary care NPs) cannot prescribe controlled substances independently.

Special considerations for PMHNPs and weight loss:

• Specialty scope: You were trained in psychiatric care, not obesity medicine. While there’s no law saying you can’t treat obesity, state boards expect you to practice within your competency. If you’re treating psychiatric patients who also have obesity (especially medication-induced), that’s a natural fit. If you’re opening a standalone weight-loss clinic with no psychiatric component, you may face scrutiny unless you have additional training.
• Controlled substances: Many weight-loss regimens include phentermine (Schedule IV). Some states have extra hurdles for NP prescribing of controlled substances. For example, Illinois requires additional pharmacology education for Schedule II prescribing, and some states require physician consultation for certain controlled drugs.
• Insurance and pharmacy barriers: Even in FPA states, insurers sometimes push back on NP-written prescriptions for expensive drugs like GLP-1s, demanding physician sign-off for prior authorizations. Some pharmacies may call your collaborating physician to verify, even if not legally required.

Practical advice for PMHNPs: If you want to prescribe weight-loss medications, secure a collaborative agreement (even in FPA states, it can smooth operations) with a physician experienced in obesity or metabolic medicine. Consider obesity medicine CME or certification to strengthen your clinical foundation.

Telehealth Prescribing: Federal vs. State Rules

Here’s where it gets tricky. Federal rules and state rules don’t always align, and you can run into compliance traps if you’re not careful.

Federal Rules (DEA/Ryan Haight Act)

Historically, the Ryan Haight Act required at least one in-person exam before prescribing controlled substances. During COVID-19, the DEA waived this requirement. As of December 2025, that waiver has been extended through December 31, 2025 (and likely into 2026), allowing providers to prescribe Schedule II–V controlled substances via telehealth without an initial in-person visit.

However, the DEA explicitly states that telehealth prescribing is only legal if it also complies with state law. This is where providers get caught.

State-Specific Telehealth Restrictions

Some states impose stricter rules than federal law:

Florida: The ‘No-Go Zone’ for Controlled Weight-Loss Drugs via Telehealth

Florida law prohibits prescribing controlled substances via telehealth except for very specific exceptions: psychiatric treatment, inpatient/hospice care, or emergency addiction treatment. Weight loss is not on the exception list.

What this means: You cannot prescribe phentermine (Schedule IV) via telehealth to Florida patients, even though federal DEA waivers allow it. You can prescribe non-controlled GLP-1 agonists (semaglutide, tirzepatide) via telehealth, as long as you meet Florida’s obesity treatment standards (documented exam, BMI criteria, quarterly follow-ups).

Workaround: Some providers arrange for patients to have an initial in-person exam with a local physician or delegate (Florida law allows a physician to delegate the initial exam to an APRN or PA), then manage follow-ups via telehealth.

Texas: Permissive for Telehealth, Strict on Delegation

Texas allows controlled substance prescribing via telehealth (following federal rules), but NPs must have a Prescriptive Authority Agreement that explicitly authorizes telehealth prescribing and the specific drugs. Texas also requires PMP checks for controlled substances and documentation that a valid patient relationship was established via adequate telehealth evaluation.

New York, Illinois, Pennsylvania, California: Generally Permissive

These states don’t impose additional telehealth restrictions beyond federal law. As long as you:

• Establish a valid patient-provider relationship (typically via live video consult for initial visit),
• Check the state prescription monitoring program (required for controlled substances),
• Follow standard of care (document exam, BMI, informed consent),

…you’re compliant.

Best practice: Don’t rely on questionnaire-only ‘asynchronous’ prescribing for weight-loss medications. A Mississippi doctor lost his license in 2023 for prescribing Ozempic via text messaging without audio-visual evaluation. Use live video visits for initial consultations and follow-ups to meet the ‘comprehensive exam’ standard most states expect.

Reimbursement: Who Pays and How Much?

Good news: insurance coverage for weight-loss medications is expanding rapidly.

Medication Coverage

Historically, Medicare Part D excluded weight-loss drugs. That changed in late 2025 when the federal government announced Medicare will begin covering anti-obesity medications like Wegovy and Mounjaro. This is a game-changer for providers serving Medicare populations.

Commercial insurance: Most major insurers now cover GLP-1 weight-loss medications, but with conditions:

• Prior authorization required: You’ll need to document BMI ≥30 (or ≥27 with comorbidities), previous attempts at lifestyle modification, and a comprehensive treatment plan.
• Step therapy: Some plans require trying older medications (like phentermine) before approving GLP-1s.
• Quantity limits: Blue Cross Blue Shield of Texas and others implemented 30-day supply limits initially to monitor adherence and prevent waste.

Medicaid: Coverage varies by state. Some state Medicaid programs already cover at least one GLP-1 for obesity; expect broader coverage following Medicare’s lead.

Visit Reimbursement

You bill standard E/M codes (99202–99215) or psychiatric codes depending on the visit type. If you’re combining weight management with psychiatric med management, code based on total complexity.

Telehealth parity: States like California, New York, Illinois, and Pennsylvania have laws requiring insurers to reimburse telehealth visits at the same rate as in-person visits. Medicare also continues to reimburse telehealth at office visit rates (extended through at least 2025).

Psychiatrist vs. PMHNP reimbursement:

• Psychiatrists (MD/DO): Reimbursed at 100% of physician fee schedule (~$75–$150 for med management visits depending on code and region).
• PMHNPs: Medicare reimburses NP services at 85% of physician rates. However, some states (like Illinois) mandate Medicaid reimburse NPs at 100% of physician rates, closing the pay gap.

Coding tip: Use obesity diagnosis codes (ICD-10 E66.*) as primary diagnosis on claims for weight management visits. Add telehealth modifier (95 or POS 02) for remote visits. Document nutrition/exercise counseling, informed consent discussion, and monitoring plans to justify higher-level E/M codes and meet state requirements.

What This Means for Your Practice

If you’re on a platform like Klarity Health, you don’t have to worry about insurance credentialing, billing, or prior authorizations — that’s handled for you. You see patients, document appropriately, and get paid per appointment. The platform model removes the financial risk of traditional marketing (no wasted ad spend, no monthly overhead for patient acquisition) and lets you focus on clinical care.

For independent practitioners, weight-loss medication management can be financially sustainable, especially via telehealth where you can see higher volumes of short follow-up visits. Just be prepared for the administrative burden of PAs and insurance requirements.

Clinical Considerations: Safety and Efficacy

Are GLP-1s safe from a psychiatric perspective?

The short answer: Yes, with appropriate monitoring.

A major concern was whether GLP-1 agonists increase depression or suicidal ideation. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo. FDA and European regulatory agencies reviewed data extensively and found no causal link. In fact, GLP-1-treated groups in clinical trials showed slightly lower rates of depressive symptoms compared to controls.

Potential mental health benefits:

• Improved mood and quality of life scores (independent of weight loss)
• Reduced cravings in patients with binge-eating or substance use issues (under investigation)
• Anti-inflammatory effects that may benefit mood disorders

Side effects to monitor:

• GI issues: Nausea, vomiting, diarrhea (common, usually mild and transient)
• Pancreatitis risk: Rare but serious; educate patients on symptoms
• Thyroid concerns: Medullary thyroid carcinoma (contraindicated in patients with family history or MEN2 syndrome)
• Drug interactions: Be aware of delayed gastric emptying affecting absorption of oral meds

Monitoring protocol:

• Baseline: BMI, vital signs, labs (A1C, lipids, kidney function, thyroid if indicated)
• Follow-up: Initially every 4 weeks to titrate dose, then every 3 months minimum (Florida requires quarterly; good practice everywhere)
• Assess for side effects, weight loss progress, and adherence to lifestyle modifications

State-by-State Quick Reference

Ethical and Practical Considerations

Is this scope creep or integrated care?

Some colleagues worry that psychiatrists prescribing weight-loss medications is ‘mission drift.’ Here’s a more useful framework: Are you treating the whole patient or chasing revenue?

If you’re managing a patient with depression and medication-induced obesity, addressing their weight with a GLP-1 while optimizing their psychiatric regimen is integrated care. If you’re pivoting your entire practice to become a cash-pay weight-loss clinic with minimal psychiatric involvement, that’s a different conversation.

Recommendations:

• Get training: At minimum, complete CME on obesity pharmacotherapy. Consider ABOM certification if you’re serious about this.
• Collaborate: Even if not legally required, consult with endocrinology or obesity medicine colleagues for complex cases.
• Document competency: In your charts and your marketing, be clear that this is part of comprehensive psychiatric care, not a side hustle.
• Refer when appropriate: Don’t try to manage severe metabolic complications (diabetic emergencies, thyroid nodules) — refer to specialists.

The business case: Weight-loss medication management can be a sustainable service line, especially as insurance coverage expands. But the real value is in keeping patients engaged in care. When you address their obesity alongside their mental health, you improve outcomes, increase satisfaction, and reduce dropouts.

How Klarity Health Simplifies This for Providers

If navigating state-by-state regulations, insurance billing, and telehealth compliance sounds overwhelming, that’s where platforms like Klarity Health come in.

What Klarity handles:

• Credentialing and licensing support across multiple states
• Pre-qualified patient flow: Patients matched to your specialty and availability
• Built-in telehealth infrastructure: HIPAA-compliant video, EHR integration, e-prescribing
• Insurance billing (for insured patients) or streamlined cash-pay workflows
• Regulatory compliance: Platform policies align with state rules (e.g., documentation standards, PMP checks)

The economic model: Pay-per-appointment instead of upfront marketing spend. No wasted budget on ads that don’t convert, no monthly subscriptions to directory sites. You pay a standard fee when a qualified patient books with you — guaranteed ROI.

For psychiatrists and PMHNPs interested in weight-loss medication management: Klarity’s model lets you expand your service offerings without the administrative burden of building your own patient acquisition funnel. You control your schedule, see patients on your terms, and get paid for every appointment.

Compare this to DIY marketing: acquiring a qualified psychiatric patient through Google Ads, SEO, or directories typically costs $200–$500+ when you factor in agency fees, ad spend testing, staff time to qualify leads, and no-show rates. SEO takes 6–12 months of consistent investment before generating meaningful patient flow. Most solo providers don’t have the expertise, budget, or patience. With Klarity, you skip the gamble and get straight to patient care.

FAQ

Can psychiatrists prescribe Wegovy or Ozempic for weight loss?

Yes. Psychiatrists (MD/DO) can prescribe FDA-approved weight-loss medications in all 50 states. Use Wegovy (semaglutide for obesity), not Ozempic (for diabetes), to stay on-label and avoid state board scrutiny (some states like Mississippi have banned off-label GLP-1 use for weight loss).

Can PMHNPs prescribe weight-loss medications independently?

It depends on your state. In full-practice-authority states (like New York after 3,600 hours, Illinois after 4,000 hours, or California starting 2026), yes. In restricted states (Texas, Florida, Alabama), you need a physician collaborative agreement that explicitly authorizes weight-loss prescribing.

Can I prescribe phentermine via telehealth?

In most states, yes (under federal DEA waivers through 2025). Exception: Florida prohibits controlled substance prescribing via telehealth unless for psychiatric treatment, so phentermine for weight loss alone is not allowed remotely in FL. Always check your state’s telehealth laws.

Do I need special certification to prescribe weight-loss medications?

No legal requirement in most states, but additional training is strongly recommended. Psychiatrists can pursue American Board of Obesity Medicine certification. NPs should take obesity medicine CME to document competency, especially if practicing outside traditional psych scope.

Will insurance cover weight-loss medications?

Increasingly, yes. Medicare will begin covering anti-obesity medications in 2026. Most commercial insurers cover GLP-1s like Wegovy with prior authorization (requiring BMI documentation, lifestyle modification attempts, etc.). Medicaid coverage varies by state.

What’s the difference between prescribing for a psych patient with obesity vs. running a weight-loss clinic?

Scope and intent. Treating obesity in patients under your psychiatric care (especially medication-induced weight gain) is integrated care within your expertise. Marketing yourself primarily as a weight-loss provider with minimal psychiatric involvement may raise scope-of-practice questions unless you have obesity medicine training/certification.

What are the monitoring requirements?

At minimum: baseline BMI, vitals, labs (A1C, lipids, kidney function). Follow-up every 4 weeks initially to titrate dose, then at least every 3 months (Florida requires quarterly; best practice everywhere). Document weight loss progress, side effects, and adherence to lifestyle modifications.

Ready to Expand Your Practice?

Weight-loss medication management represents a real opportunity for psychiatrists and PMHNPs — not just financially, but clinically. You’re already treating the mental health consequences of obesity and medication-induced weight gain. With the right training and compliance framework, prescribing GLP-1s or other weight-loss medications can be a natural extension of comprehensive psychiatric care.

If you want to offer these services without the headache of building your own patient acquisition system, join Klarity Health’s provider network. Get matched with pre-qualified patients, use our built-in telehealth platform, and focus on what you do best: providing great care.

Visit Klarity Health to learn more about joining our provider network and expanding your practice into metabolic-psychiatric care.

Sources

1. MedicalDirector Co. (2025). How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? 2025 Definitive Guide. https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/

2. MedicalDirector Co. (2025). Florida Weight Loss Clinic and Telehealth Compliance Guide. https://www.medicaldirectorco.com/florida-weight-loss-clinic-and-telehealth-compliance-guide-2025/

3. MedicalDirector Co. (2025). Texas Weight Loss Clinic & Telehealth Compliance Guide. https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

4. Florida Administrative Code R. 64B15-14.004 (effective Aug 8, 2022). Standards for Prescription of Obesity Drugs. https://www.law.cornell.edu/regulations/florida/Fla-Admin-Code-Ann-R-64B15-14-004

5. Foley & Lardner LLP via Mondaq (July 24, 2023). A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs. https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs

Note: This content is for informational purposes only and does not constitute legal or medical advice. State laws and regulations change frequently. Consult your state medical/nursing board and legal counsel for specific compliance guidance.